Not Disclosed

Drug Name: Not Disclosed
Company: Yumanity Therapeutics
Location: US-Massachusetts
Website: http://www.yumanity.com
Drug Type: Small Molecule
Conditions: ALS, Parkinson’s disease, Alzheimer’s disease
Mechanism Type: Proteostasis, Protein misfolding modulators
Mechanism: Yumanity’s innovative new approach to drug discovery and development concentrates on reversing the cellular phenotypes and disease pathologies caused by protein misfolding. Yumanity’s discovery platform combines high-throughput screening in yeast cells with a human neural platform composed of induced pluripotent stem cells from patients, which allows for iterative and parallel analysis of results in both systems. In addition, the company has a drug-target identification platform that leverages yeast genetics and analysis of protein networks to identify drug targets. The company’s lead candidate is for Parkinson’s disease.
U.S. Status for ALS: Preclinical

References:
[1] From yeast to patient neurons and back again: powerful new discovery platform. Tardiff, DF et al. Mov Disord. 2014 Sep;29(10):1231-40.

Last updated March 11th, 2016

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail